CL7 1.5 mg (Rivastigmine Tartrate 1.5 mg)
Pill with imprint CL7 1.5 mg is Yellow, Capsule-shape and has been identified as Rivastigmine Tartrate 1.5 mg. It is supplied by Macleods Pharmaceuticals Limited.
Rivastigmine is used in the treatment of alzheimer's disease; parkinson's disease and belongs to the drug class cholinesterase inhibitors. There is no proven risk in humans during pregnancy. Rivastigmine 1.5 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for CL7 1.5 mg
Rivastigmine Tartrate
- Imprint
- CL7 1.5 mg
- Strength
- 1.5 mg
- Color
- Yellow
- Shape
- Capsule-shape
- Availability
- Prescription only
- Drug Class
- Cholinesterase inhibitors
- Pregnancy Category
- B - No proven risk in humans
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Macleods Pharmaceuticals Limited
- National Drug Code (NDC)
- 33342-0089
- Inactive Ingredients
-
magnesium stearate,
microcrystalline cellulose,
silicon dioxide,
gelatin,
titanium dioxide,
sodium lauryl sulfate,
ferric oxide red,
ferric oxide yellow,
hypromelloses
Note: Inactive ingredients may vary.
More about rivastigmine
- Side effects
- Drug interactions
- Dosage information
- During pregnancy
- Reviews (34)
- Drug images
- Pricing & coupons
- Drug class: cholinesterase inhibitors
Patient resources
- Drug Information
- Rivastigmine transdermal
- Rivastigmine Transdermal (Advanced Reading)
- Rivastigmine Capsules
- Rivastigmine Oral Solution
- Rivastigmine Patch
Other brands
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.